Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
종목 코드 BBLG
회사 이름Bone Biologics Corp
상장일Nov 27, 2015
CEOMr. Jeffrey Frelick
직원 수2
유형Ordinary Share
회계 연도 종료Nov 27
주소2 Burlington Woods Dr Ste 100
도시BURLINGTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호01803-4551
전화17815524452
웹사이트https://www.bonebiologics.com/
종목 코드 BBLG
상장일Nov 27, 2015
CEOMr. Jeffrey Frelick
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음